Smartleaf Asset Management’s ImmunityBio IBRX Stock Holding History

Smartleaf Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.2K	Buy	+1,150	New	+$9.19K	﹤0.01%	2428

Other funds holding IBRX

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Smartleaf Asset Management's IBRX Position: Q3 2026 in Review

Smartleaf Asset Management opened a new position in ImmunityBio (IBRX) in Q3 2026: 1,150 shares worth $10.2K. The stake represents ﹤0.01% of the portfolio and ranks #2428 among its holdings.

283 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

Smartleaf Asset Management held 1,150 shares of ImmunityBio worth $10.2K as of Q3 2026.
ImmunityBio was a new Smartleaf Asset Management position in Q3 2026.
ImmunityBio made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #2428 holding.
283 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.